Optical Control of Insulin Secretion Using an Incretin Switch

Johannes Broichhagen, Tom Podewin, Helena Meyer-Berg, Yorrick Von Ohlen, Natalie R. Johnston, Ben J. Jones, Stephen R. Bloom, Guy A. Rutter, Anja Hoffmann-Röder, David J. Hodson, Dirk Trauner

Research output: Contribution to journalArticle

Abstract

Incretin mimetics are set to become a mainstay of type 2 diabetes treatment. By acting on the pancreas and brain, they potentiate insulin secretion and induce weight loss to preserve normoglycemia. Despite this, incretin therapy has been associated with off-target effects, including nausea and gastrointestinal disturbance. A novel photoswitchable incretin mimetic based upon the specific glucagon-like peptide-1 receptor (GLP-1R) agonist liraglutide was designed, synthesized, and tested. This peptidic compound, termed LirAzo, possesses an azobenzene photoresponsive element, affording isomer-biased GLP-1R signaling as a result of differential activation of second messenger pathways in response to light. While the trans isomer primarily engages calcium influx, the cis isomer favors cAMP generation. LirAzo thus allows optical control of insulin secretion and cell survival. Incretins in the spotlight: An azobenzene photoswitch was placed between the alpha helices of the incretin mimetic liraglutide to yield isomer-biased optical control over glucagon-like peptide-1 receptor (GLP-1R) signaling, pancreatic beta cell function, and insulin release.

Original languageEnglish (US)
Pages (from-to)15565-15569
Number of pages5
JournalAngewandte Chemie - International Edition
Volume54
Issue number51
DOIs
StatePublished - Dec 14 2015

Fingerprint

Incretins
Insulin
Isomers
Switches
Peptides
Azobenzene
Medical problems
Second Messenger Systems
Calcium
Brain
Chemical activation
Cells
Glucagon-Like Peptide-1 Receptor

Keywords

  • beta cells
  • insulin
  • liraglutide
  • photopharmacology
  • type 2 diabetes

ASJC Scopus subject areas

  • Catalysis
  • Chemistry(all)

Cite this

Broichhagen, J., Podewin, T., Meyer-Berg, H., Von Ohlen, Y., Johnston, N. R., Jones, B. J., ... Trauner, D. (2015). Optical Control of Insulin Secretion Using an Incretin Switch. Angewandte Chemie - International Edition, 54(51), 15565-15569. https://doi.org/10.1002/anie.201506384

Optical Control of Insulin Secretion Using an Incretin Switch. / Broichhagen, Johannes; Podewin, Tom; Meyer-Berg, Helena; Von Ohlen, Yorrick; Johnston, Natalie R.; Jones, Ben J.; Bloom, Stephen R.; Rutter, Guy A.; Hoffmann-Röder, Anja; Hodson, David J.; Trauner, Dirk.

In: Angewandte Chemie - International Edition, Vol. 54, No. 51, 14.12.2015, p. 15565-15569.

Research output: Contribution to journalArticle

Broichhagen, J, Podewin, T, Meyer-Berg, H, Von Ohlen, Y, Johnston, NR, Jones, BJ, Bloom, SR, Rutter, GA, Hoffmann-Röder, A, Hodson, DJ & Trauner, D 2015, 'Optical Control of Insulin Secretion Using an Incretin Switch', Angewandte Chemie - International Edition, vol. 54, no. 51, pp. 15565-15569. https://doi.org/10.1002/anie.201506384
Broichhagen J, Podewin T, Meyer-Berg H, Von Ohlen Y, Johnston NR, Jones BJ et al. Optical Control of Insulin Secretion Using an Incretin Switch. Angewandte Chemie - International Edition. 2015 Dec 14;54(51):15565-15569. https://doi.org/10.1002/anie.201506384
Broichhagen, Johannes ; Podewin, Tom ; Meyer-Berg, Helena ; Von Ohlen, Yorrick ; Johnston, Natalie R. ; Jones, Ben J. ; Bloom, Stephen R. ; Rutter, Guy A. ; Hoffmann-Röder, Anja ; Hodson, David J. ; Trauner, Dirk. / Optical Control of Insulin Secretion Using an Incretin Switch. In: Angewandte Chemie - International Edition. 2015 ; Vol. 54, No. 51. pp. 15565-15569.
@article{86ac45ac719b402e8d8f30f30a097d95,
title = "Optical Control of Insulin Secretion Using an Incretin Switch",
abstract = "Incretin mimetics are set to become a mainstay of type 2 diabetes treatment. By acting on the pancreas and brain, they potentiate insulin secretion and induce weight loss to preserve normoglycemia. Despite this, incretin therapy has been associated with off-target effects, including nausea and gastrointestinal disturbance. A novel photoswitchable incretin mimetic based upon the specific glucagon-like peptide-1 receptor (GLP-1R) agonist liraglutide was designed, synthesized, and tested. This peptidic compound, termed LirAzo, possesses an azobenzene photoresponsive element, affording isomer-biased GLP-1R signaling as a result of differential activation of second messenger pathways in response to light. While the trans isomer primarily engages calcium influx, the cis isomer favors cAMP generation. LirAzo thus allows optical control of insulin secretion and cell survival. Incretins in the spotlight: An azobenzene photoswitch was placed between the alpha helices of the incretin mimetic liraglutide to yield isomer-biased optical control over glucagon-like peptide-1 receptor (GLP-1R) signaling, pancreatic beta cell function, and insulin release.",
keywords = "beta cells, insulin, liraglutide, photopharmacology, type 2 diabetes",
author = "Johannes Broichhagen and Tom Podewin and Helena Meyer-Berg and {Von Ohlen}, Yorrick and Johnston, {Natalie R.} and Jones, {Ben J.} and Bloom, {Stephen R.} and Rutter, {Guy A.} and Anja Hoffmann-R{\"o}der and Hodson, {David J.} and Dirk Trauner",
year = "2015",
month = "12",
day = "14",
doi = "10.1002/anie.201506384",
language = "English (US)",
volume = "54",
pages = "15565--15569",
journal = "Angewandte Chemie - International Edition",
issn = "1433-7851",
number = "51",

}

TY - JOUR

T1 - Optical Control of Insulin Secretion Using an Incretin Switch

AU - Broichhagen, Johannes

AU - Podewin, Tom

AU - Meyer-Berg, Helena

AU - Von Ohlen, Yorrick

AU - Johnston, Natalie R.

AU - Jones, Ben J.

AU - Bloom, Stephen R.

AU - Rutter, Guy A.

AU - Hoffmann-Röder, Anja

AU - Hodson, David J.

AU - Trauner, Dirk

PY - 2015/12/14

Y1 - 2015/12/14

N2 - Incretin mimetics are set to become a mainstay of type 2 diabetes treatment. By acting on the pancreas and brain, they potentiate insulin secretion and induce weight loss to preserve normoglycemia. Despite this, incretin therapy has been associated with off-target effects, including nausea and gastrointestinal disturbance. A novel photoswitchable incretin mimetic based upon the specific glucagon-like peptide-1 receptor (GLP-1R) agonist liraglutide was designed, synthesized, and tested. This peptidic compound, termed LirAzo, possesses an azobenzene photoresponsive element, affording isomer-biased GLP-1R signaling as a result of differential activation of second messenger pathways in response to light. While the trans isomer primarily engages calcium influx, the cis isomer favors cAMP generation. LirAzo thus allows optical control of insulin secretion and cell survival. Incretins in the spotlight: An azobenzene photoswitch was placed between the alpha helices of the incretin mimetic liraglutide to yield isomer-biased optical control over glucagon-like peptide-1 receptor (GLP-1R) signaling, pancreatic beta cell function, and insulin release.

AB - Incretin mimetics are set to become a mainstay of type 2 diabetes treatment. By acting on the pancreas and brain, they potentiate insulin secretion and induce weight loss to preserve normoglycemia. Despite this, incretin therapy has been associated with off-target effects, including nausea and gastrointestinal disturbance. A novel photoswitchable incretin mimetic based upon the specific glucagon-like peptide-1 receptor (GLP-1R) agonist liraglutide was designed, synthesized, and tested. This peptidic compound, termed LirAzo, possesses an azobenzene photoresponsive element, affording isomer-biased GLP-1R signaling as a result of differential activation of second messenger pathways in response to light. While the trans isomer primarily engages calcium influx, the cis isomer favors cAMP generation. LirAzo thus allows optical control of insulin secretion and cell survival. Incretins in the spotlight: An azobenzene photoswitch was placed between the alpha helices of the incretin mimetic liraglutide to yield isomer-biased optical control over glucagon-like peptide-1 receptor (GLP-1R) signaling, pancreatic beta cell function, and insulin release.

KW - beta cells

KW - insulin

KW - liraglutide

KW - photopharmacology

KW - type 2 diabetes

UR - http://www.scopus.com/inward/record.url?scp=84955181360&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84955181360&partnerID=8YFLogxK

U2 - 10.1002/anie.201506384

DO - 10.1002/anie.201506384

M3 - Article

VL - 54

SP - 15565

EP - 15569

JO - Angewandte Chemie - International Edition

JF - Angewandte Chemie - International Edition

SN - 1433-7851

IS - 51

ER -